Blue Trust Inc. Acquires 154 Shares of Illumina, Inc. (NASDAQ:ILMN)

Blue Trust Inc. boosted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 17.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,037 shares of the life sciences company’s stock after purchasing an additional 154 shares during the quarter. Blue Trust Inc.’s holdings in Illumina were worth $135,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in ILMN. Versant Capital Management Inc boosted its position in shares of Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 146 shares during the last quarter. TD Private Client Wealth LLC lifted its stake in Illumina by 58.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after purchasing an additional 141 shares in the last quarter. Private Trust Co. NA boosted its holdings in shares of Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after purchasing an additional 212 shares during the last quarter. Focused Wealth Management Inc purchased a new position in shares of Illumina during the third quarter valued at about $63,000. Finally, Hollencrest Capital Management purchased a new position in shares of Illumina during the third quarter valued at about $63,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Trading Up 0.4 %

ILMN stock opened at $124.68 on Thursday. Illumina, Inc. has a 12 month low of $100.08 and a 12 month high of $156.66. The firm’s 50-day moving average is $138.19 and its 200 day moving average is $135.50. The company has a market capitalization of $19.77 billion, a PE ratio of -12.52 and a beta of 1.10. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85.

Illumina (NASDAQ:ILMN) last issued its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same period last year, the company posted $0.33 earnings per share. The company’s quarterly revenue was down 3.5% compared to the same quarter last year. On average, research analysts anticipate that Illumina, Inc. will post 4.13 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on ILMN. Citigroup lowered Illumina from a “buy” rating to a “neutral” rating and dropped their price target for the company from $190.00 to $165.00 in a research note on Wednesday, December 11th. UBS Group raised their target price on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Royal Bank of Canada upped their price target on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Morgan Stanley dropped their price objective on shares of Illumina from $156.00 to $150.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, TD Cowen upped their target price on shares of Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Eight research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $164.84.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.